Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440985 | 0.86 | MCL1 (0.76) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6752295 | 0.86 | MCL1 (0.76) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3534182 | 0.85 | MCL1 (0.73) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1096760 | 0.82 | L3MBTL1 (0.70) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31435640 | 0.82 | MCL1 (0.69) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10084917 | 0.82 | MCL1 (0.69) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5599830 | 0.81 | KDM4E (0.68) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2001537 | 0.81 | HSD17B10 (0.68) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30547707 | 0.81 | KDM4E (0.68) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5889548 | 0.81 | KDM4E (0.68) | MCL1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024155601-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2023226950-A1 | PEPTIDOMIMETIC STAT PROTEIN DEGRADER, COMPOSITION AND USE THEREOF | 杭州和正医药有限公司 | 2023-11-30 | — | — | WO | disclosed |
| CN-117126231-A | Peptoid STAT protein degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-114702504-B | Trifluoromethyl substituted indolopyranone compound, preparation method thereof and application thereof in antitumor drugs | 平顶山学院 | 2023-04-07 | — | — | CN | disclosed |
| CN-114702504-A | Trifluoromethyl substituted indolopyranone compound, preparation method thereof and application thereof in antitumor drugs | 平顶山学院 | 2022-07-05 | — | — | CN | disclosed |
| EP-3400210-B1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIV PARIS SACLAY (FR) | 2021-09-29 | — | — | EP | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| CN-109705071-A | Hdac inhibitor and its preparation method and application | 成都先导药物开发有限公司 | 2019-05-03 | — | — | CN | disclosed |
| EP-3400210-A2 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | Universite Paris-Sud (FR) | 2018-11-14 | — | — | EP | disclosed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-6989384-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| CN-1525957-A | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | ������ҩ������˾ | 2004-09-01 | — | — | CN | disclosed |
| US-6632825-B2 | Picornaviral 3C protease enzyme inhibitors; amide ester or amide acid derivatives | AGOURON PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, FFAR1 | MCL1 2050/4885KDM4E 4119/4885ALDH1A1 242/4885 |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MCL1 1264/4885KDM4E 4218/4885ALDH1A1 3253/4885 |
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | MCL1 3640/4885KDM4E 3080/4885ALDH1A1 4076/4885 |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNASEL, RNASEH1 | MCL1 3478/4885KDM4E 3119/4885ALDH1A1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.